RxDoctor Payments Data

Luis Tami, MD

Cardiovascular Disease · Hollywood, FLNPI 1558302638

Payments from drug & device makers

$606,483in general payments, 2019–2025

Across 462 payments — averaging $1312.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$508K
  • Abbott$45K
  • Biotronik Inc.$19K
  • AstraZeneca$11K
  • Merck$10K
  • Edwards Lifesciences$4K
  • plus $10K from 34 others

What the payments were for

  • Speaking & faculty fees$9,98443%
  • Grants$2001%
  • Travel & lodging$1,3636%
  • Food & beverage$11,60450%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$606,483 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$538,439
Medicare patients
1,010
Services billed
5,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban415$467,766
EntrestoSacubitril/Valsartan343$381,581
FarxigaDapagliflozin Propanediol196$194,660
Repatha SureclickEvolocumab122$87,239
BrilintaTicagrelor90$75,364
XareltoRivaroxaban74$73,480
JardianceEmpagliflozin41$46,798
Repatha SyringeEvolocumab51$43,748
OzempicSemaglutide25$25,727
VascepaIcosapent Ethyl19$15,214
DapagliflozinDapagliflozin Propanediol27$13,143
MounjaroTirzepatide11$11,346
Praluent PenAlirocumab18$8,860
Midodrine Hcl40$8,118
Nifedipine ErNifedipine216$7,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$425$467,766415 claims
NovartisEntresto$1,405$381,581343 claims
AstraZenecaFarxiga, Brilinta$10,505$270,024286 claims
Johnson & JohnsonXarelto$751$73,48074 claims
Boehringer IngelheimJardiance$143$46,79841 claims
Novo NordiskOzempic$326$25,72725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →